← All Gb Sciences INC filings

Gb Sciences INC 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

OTC.Pink
GBLX
Gb Sciences INC
8-K: GB Sciences Licenses Parkinson's Treatment to EndoPure, Secures 5% Royalty and Clinical Trial Funding
GB Sciences has entered an exclusive licensing agreement with EndoPure Life Sciences for its cannabinoid-based Parkinson's treatment, securing a 5% royalty on gross sales and funding for first-in-human clinical trials in South America.
OTC.Pink
GBLX
Gb Sciences INC
8-K: GB Sciences Announces Leadership Transition Following Passing of CEO John Poss
GB Sciences appoints Dr. Andrea Small-Howard as CEO, CFO, and Chairman of the Board following the passing of former CEO John Poss.
OTC.Pink
GBLX
Gb Sciences INC
8-K: GB Sciences Inks Letter of Intent with EndoPure for South American Market Expansion
GB Sciences has signed a non-binding letter of intent with EndoPure Life Sciences to license its intellectual property for pharmaceutical product development and marketing in South America.